poisar

Stocks · News reference

Callan JMB Inc. Reports Third Quarter 2026 Financial Results

Fiscal.ai

Callan JMB Inc. announced its financial results for the third quarter of 2026, reporting a loss per share of $0.44 compared to a loss of $0.61 in the same period last year.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — CALLAN JMB INC. (CJMB)

    Filed: 2026-11-13 AccNo: 0001493152-26-051752 Size: 831 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

  2. Globenewswire IncNa

    Callan JMB Announces Arrival of Rapid Dose Therapeutics’ QuickStrip™, Resulting in $15 Million in Projected Revenue Over the Next 18 months

    Callan JMB has received a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics for installation at its Texas facility. The company projects $15 million in revenue over the next 18 months from this new pharmaceutical manufacturing platform, advancing its strategy to expand domestic pharmaceutical manufacturing and healthcare logistics capabilities.